Sign up to get each new magazine issue delivered to your inbox

Next Issue

July 2022

Despite a slower start in the immuno-oncology arena, China appears to have surpassed its Western counterparts in building a strong research pipeline of specialised CAR-T therapies. Next month, with the help of data, we’ll track the rise of cell therapy research, and more specifically CAR-Ts, in China and how that compares to the rest of the world. 


With between 100 and 400 million dengue fever infections each year, pharma manufacturers need to overcome several obstacles to developing antiviral treatments and vaccines. In July, we’ll take a look at the candidates in the clinic, and what can be expected in the pipeline in the near future.  


All this plus the latest trends and innovations in the pharma industry, as well as up-to-date analysis and insight from GlobalData experts. 

EDITORIAL

Editor | Manasi Vaidya

Writers | Mengying Du, Urte Fultinaviciute, Isabeau van Halm, Saywah Mahmood, William Newton, Mirela Petkova, Adam Zamecnik 
Magazine Designer | Maria Gimenez, Martina Labaiova

Graphic Designers | Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Will Ingham
Lead Designer | John Hammond 

Publisher | Susanne Hauner

Advertising

Sales Manager | Tom McCormick

+44 207 8669440

Pharma Technology Focus is powered by H5mag

Read past issues of Pharma Technology Focus HERE

Copyright 2022 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | Continuous manufacturing cautiously builds on hypeGo to article: In this issueGo to article: CSafe GlobalGo to article: ContentsGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: SHL Medical Company Insight Go to article: SHL MedicalGo to article: WR GraceGo to article: CommentGo to article: CMO agreements need to go public, but ‘glib’ onshoring not the answerGo to article: Biologic sales forecast to pass innovative small molecule sales in next five yeaGo to article: The telemedicine community has rallied to provide support to patients in UkraineGo to article: Osteoarthritis pipeline shifting from analgesics to disease-modifying treatmentsGo to article: BioLife SolutionsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: In DepthGo to article: Continuous manufacturing builds on hype but adoption remains gradual Go to article: Can Relmada’s fast-acting pill for major depressive disorder compete inGo to article: Access to CAR-T therapies in Central and Eastern Europe in “catch-up” mode compaGo to article: How ambitious are the emissions targets of pharma and biotech companies?Go to article: Should Covid-19 clinical trial plans still centre around EUAs?Go to article: BEA TechnologiesGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: In DataGo to article: Top and emerging locations for M&A deals in the pharma industryGo to article: Deals relating to genomics increased in the pharma industry in H2 2021Go to article: Pharma industry companies are increasingly innovating in machine learningGo to article: BaxterGo to article: EventsGo to article: Next issue